PCN53 THE BURDEN OF MANAGING PLEURAL EFFUSIONS IN CML PATIENTS POST-IMATINIB FAILURE: A LITERATURE-BASED ECONOMIC ANALYSIS
Stephens JM 1 , Carpiuc KT 1 , Botteman MF 1 , Feng W 2 1 Pharmerit North America LLC, Bethesda, MD, USA, 2 Novartis Pharmaceuticals, Florham Park, NJ, USA OBJECTIVE: To develop an economic analysis of the management of pleural effusions in CML patients receiving dasatinib. METHODS: A cost of treatment analysis was developed using resource utilization data published for 48 patients with dasatinib-related pleural effusions at a large cancer center. Costs were derived from median reimbursements for relevant CPT codes for outpatient services and medical literature for inpatient services. The base case analysis assumed 100% incurred two additional physician visits, two chest x-rays, and a course of diuretics; 37.5% ECHO; 30% steroids; 24% recurrent effusions; 19% multiple thoracentesis procedures; 4% chest tube; 4% Denver shunt; and 2% pericardial window. Sensitivity analyses were conducted for types of procedures used. All costs were adjusted to 2007 US dollars. RESULTS: Of pleural effusions reported, 58% involved Յ 25% of one lung volume and were managed medically costing $750 per episode, including physician visits, ECHO, chest X-rays and medications. The other 42% of pleural effusions were more significant, involving 26%->75% of one lung volume, with half of those patients requiring invasive procedures. The cost of invasive procedures for inpatient management of pleural effusions was $10,616 for chest tube, $15,170 with pleural catheter, and $15,344 for pericardial window. The cost of invasive outpatient management ranged from $713 for ultrasound thoracentesis to $4598 for pleural catheter. The average cost of treating a pleural effusion adverse event (including all severity levels) ranged from $2062 to >$3000 depending on whether thoracentesis or placement of pleural catheter was utilized. Important drivers included recurrent effusions. CON-CLUSION: This economic analysis based on actually observed treatment patterns suggests that the management of pleural effusions in CML patients receiving dasatinib is costly and requires intensive resource utilization. Effective tyrosine kinase inhibitors with lower rates of pleural effusions may represent clinically and economically valuable alternatives for imatinib-resistant or -intolerant CML patients.
PCN54 A COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS VERSUS SECONDARY PROPHYLAXIS WITH COLONY-STIMULATING FACTOR IN ELDERLY PATIENTS WITH DIFFUSE AGGRESSIVE LYMPHOMA RECEIVING CURATIVE-INTENT CHEMOTHERAPY USING ONTARIO HEALTH ECONOMIC DATA
Chan KKW 1 , Krahn MD 2 , Imrie K 3 , Alibhai SM 2 1 R.S. McLaughlin Durham Regional Cancer Centre, Oshawa, ON, Canada, 2 University Health Network, Toronto, ON, Canada, 3 University of Toronto, Toronto, ON, Canada OBJECTIVE: The 2006 American Society of Clinical Oncology guideline recommends primary prophylaxis (PP) with colonystimulating factor (CSF) for elderly patients with diffuse aggressive lymphoma receiving chemotherapy, based on the assumption of equal survival and studies showing that CSF saved costs by reducing hospitalization from febrile neutropenia (FN). These analyses examined only one cycle of chemotherapy, and did not consider the costs of CSF in subsequent cycles, the strategy of secondary prophylaxis (SP) or patients' preferences. This study examined the cost-effectiveness of PP with SP. METHODS: We conducted a cost-utility analysis to compare PP with CSF to SP with CSF for diffuse aggressive lymphoma. We used a Markov cohort model with a time horizon of 8 cycles of chemotherapy (i.e. 24 weeks), using a payer's perspective (Ontario Ministry of Health). Ontario's 2006 health economic data was used. The cost of hospitalization for FN was obtained from Ontario Case Costing Initiative. Data for efficacies of CSF, probabilities and utilities were obtained from published literature. Monte Carlo simulation was conducted. RESULTS: The ICER of PP to SP was $739,999/QALY. One-way sensitivity analyses (willingness-topay threshold =$100,000) showed that if PP were to be costeffective, the cost of hospitalization for FN had to be >$31,138 (2.5 times > base case), the cost of CSF per cycle <$96 (base case = $1960), the risk of 1st cycle FN >48% (base case = 24%), or the relative risk reduction of FN with CSF >97% (base case = 41%). Our result was robust to all variables. Second order A70 Abstracts probabilistic sensitivity analysis revealed a 10% probability of PP being cost-effective over SP at a willingness-to-pay threshold of $100,000. CONCLUSION: PP is not cost-effective when compared with SP under most assumptions. The costs of CSF and hospitalization in all cycles should be accounted for in economic evaluations of CSF.
PCN55 A COST-UTILITY ANALYSIS OF FULVESTRANT IN TREATING RECURRENT METASTATIC BREAST CANCER
Park SY, Kang HH, Noh E, Lee EK Sook Myung Women's University, Seoul, South Korea OBJECTIVE: The objective of the study is to evaluate costeffectiveness of two sequential treatments; with Fulvetsrant sequence and without Fulvestrant sequence in the treatment of postmenopausal women with hormone receptor-positive local advanced or recurrent metastatic breast cancer in Korea.
METHODS:
We developed a Markov model which allows assessments of the two sequential treatments to simulate the course of patients following each treatment pathway, estimating health outcomes through a long-term observation. The model was constructed with data from the literature and expert opinions. Markov health states was consisted of stable/responding, progressive, and death. The Markov cycle length is 28 days for each treatment and the cohort size is 1000 patients for each cohort. This study was analyzed from a societal perspective. All cost and outcomes were discounted at 5% and currency rate was applied to U.S. dollars. One-way sensitivity analysis and probabilistic sensitivity analysis were conducted. RESULTS: The base case results that Cohort A (with Fulvestrant) had 1.037 QALY and Cohort B (without Fulvestrant) did 0.822 QALY at year 10. The expected costs results Cohort A spent $2704 more per patient; Cohort A $16,265 and Cohort B $13,562, respectively. The resulting ICER Per QALY was $9513 for cohort A to obtain a quality adjusted life year with respect to Cohort B in the 10year model. The results of one-way sensitivity analysis showed stable; however; that of probability sensitivity analysis resulted from $15,796 to $16,863 with a range of QALY per person at 0.6964~0.8704 within 95% CI. CONCLUSION: Ten-year model of Cohort A in the treatment of postmenopausal women with hormone receptor-positive local advanced or recurrent metastatic breast cancer showed better clinical outcomes than Cohort B.
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NAB-PACLITAXEL OR DOCETAXEL; AS ALTERNATIVES TO CONVENTIONAL PACLITAXEL FOR THE TREATMENT OF METASTATIC BREAST CANCER (MBC): A COST UTILITY ANALYSIS IN FIVE EUROPEAN COUNTRIES
Dranitsaris G 1 , Lidgren M 2 , Lundkvist J 2 , Coleman R 3 1 Augmentium Pharma Consulting, Toronto, ON, Canada, 2 I3 Innovus, Stockholm, Sweden, 3 Weston Park Hospital, Sheffield, UK OBJECTIVE: In patients with MBC, a common practice in Europe is to offer first line docetaxel or paclitaxel. However, one important drawback in their use is the potential for dose-limiting toxicity. An albumin-bound formulation (nab) of paclitaxel (Abraxane) was recently developed to overcome these safety drawbacks and to provide additional efficacy. To provide health economic data, a cost utility analysis comparing nab-paclitaxel to docetaxel, both as alternatives to paclitaxel was conducted for the United Kingdom (UK), France, Germany, Italy and Spain. METHODS: The clinical data were obtained from a meta analysis of randomized trials. Health care resource use for the delivery of chemotherapy and the management of grade III/IV toxicity was collected from a survey of European medical oncologists and from the literature. Using the Time Trade-off technique, utilities were obtained from 70 female oncology nurses in the UK and France. RESULTS: Nab-paclitaxel had the most favourable safety profile with the lowest incidence of grade III/IV neutropenia, febrile neutropenia, anemia, emesis and stomatitis. This translated to lower overall costs for managing the grade III/IV toxicity relative to both docetaxel and paclitaxel (e.g. in France; €286 vs. €966 vs. €422). Using the median number of cycles administered and the cost of toxicity in each country, the overall cost for nab-paclitaxel was higher than conventional paclitaxel, but comparable to docetaxel. Overall, 47 of 70 (67.1%) respondents selected nab-paclitaxel as their preferred choice. As an alternative to paclitaxel, the incremental cost per QALY gained was lower for nab-paclitaxel than docetaxel in three of the five countries evaluated. CONCLUSION: Given its more favorable safety profile, improved efficacy and comparable overall cost, nab-paclitaxel can be considered a preferred option over docetaxel in MBC. As an alternative to paclitaxel, each of the European health care bodies must decide if the cost per QALY gained for that country represents good value.
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COST-UTILITY ANALYSIS OF ADJUVANT GOSERELIN AND ADJUVANT CHEMOTHERAPY IN PATIENTS WITH PREMENOPAUSAL BREAST CANCER
Cheng TF Shin Kong Wu Ho-Su Memorial Hospital, Taipei City, Taiwan OBJECTIVE: To compare the cost and utility of adjuvant Goserelin and adjuvant chemotherapy for premenopausal breast cancer patients in Taiwan. METHODS: A total of 564 premenopausal breast cancer patients were newly diagnosed since 1993. Their medical history and vital status were routinely reviewed and recorded. From July 2007 to December 2007, 105 patients with stage Ia-IIIa disease who received Goserelin for at least one year or received at least 6 cycles of chemotherapy as adjuvant therapy were interviewed to obtain the utility value by standard gambling (SG) and visual scale (VS) methods. The chemotherapy included four regimens: CMF (cyclophosphamide, methotrexate, 5-fluorouracil), TE (docetaxel, epirubicin), TEC (docetaxel, epirubicin, cyclophosphamide), and CEF (cyclophosphamide, epirubicin, 5-fluorouracil). The cost of this study was defined as the total medical cost (surgery, drugs, and all services provided costs) of standard practices from a payer perspective. The standard practices of Goserelin and chemotherapy were subcutaneous injection of 3.6 mg Goserelin every four weeks for two years and six cycles of CMF, TE, TEC, or CEF, respectively. Survival analysis was conducted by Kaplan-Meier method and weighted by utility measurements. RESULTS: Survival at 11 years derived from registry data for patients received Goserelin was better than patients received chemotherapy (100% vs. 75%). Combining the survival data with utility score from questionnaires, the utilityweighted life-years were higher in Goserelin group compared to chemotherapy group by SG and VS 8.81 vs. 6.83, 8.78 vs. 7 .14, respectively. The cost of Goserelin was lower than that of chemotherapy and ranged from NT$29,825 to 50,234 (US$918-1,545) when applying standard body surface of 1.5 m 2 and 1.8 m 2 about the calculation of chemotherapy doses. CONCLU-SION: Our data suggest the Goserelin had better survival, higher utility-weighted life-years, but less cost than chemotherapy in the adjuvant treatment of premenopausal patients with stage Ia-IIIa breast cancer in Taiwan.
